Page 19 - CIBERSAM-2015-eng

Schizophrenia
COORDINATOR: DR. JULIO SANJUÁN ARIAS (G23 – Facultad Medicina. Universitat de València)
Scientific Programmes
The Schizophrenia programme covers the largest number of research groups in the CIBERSAM (12) and has the main purpose of multidisciplinary study of this Severe Mental Disorder. Although research into biological bases has been prevalent, this progress needs to be combined with psycho-social interven- tion programmes and requires this research to be per-
Different basic groups of the CIBERSAM have pub- lished and proposed new models for prediction of re- sponse to antipsychotics.
• Researching into the efficiency and effectiveness of psychotherapeutic treatments in combination with the customary pharmacological treatments in schizophrenia. Several European Projects have
ceived by users as an improvement in the quality of the care given.
This extensive participation, combined with the Com- mon Database and different collaborative studies, makes it the programme with the largest clinical and genetic database. Some major cooperative projects have been carried out on the development of the first psychotic episodes. In 2015 175 studies were pub- lished, raising the previous year’s production by 10% and the number of citations went from 1150 to 1720 in just one year. This reflects the qualitative increase in the type of publications in this programme.
Lines of research:
• Continuing the study of follow-up and predictive variables in first psychotic episodes.
• In 2015 work went on with the publication of the results of the PEPs study on first psychotic epi- sodes (stressing the first publication of neuroim- aging in Schizophrenia Bulletin, 1st Decile), with the Second PEPs project, both coordinated by Dr. Bernardo and with the publications of the Euro- pean EU-GEI project coordinated in Spain by Dr. Arango.
• Studying the possible neurobiological markers (genetic, immunological and neuroimaging) of the different symptomatological phenotypes of schizophrenia. We took part in an important pub- lication on how the genes involved in GWAS bear a relation with immunological mechanisms (Na- ture Neuroscience 18, 2, 2015).
• Studying the role of schizotypal personality with regard to the prognosis and evolution of these pa- tients.
• Studying the predictive variables of response to different pharmacological treatments.
been got under way with the participation of CIBERSAM groups (Dr. Arango, Dr. Crespo-Facor- ro, Dr. Bernardo) with the main aim of optimising pharmacological and psychosocial treatment.
• Studying the repercussions of schizophrenia in the state of health, psychosocial adjustment, quality of life, levels of individuals’ disability and in the patterns of use of services by these patients and their influence on comorbidity.
As well as the participation in over 40 projects con- nected with psychosis in 2015 the following achieve- ments should be highlighted:
• Participation in European projects such as OPTi- MiSE, EU-GEI, EULAST.
• The project Understanding Obesity, Metabolic Syndrome Type 2 Diabetes: a multidisciplinary approach, in the call arranged by the MINECO and ISCIII, integrated excellence projects 2014.
• A patent for a new method for monitoring antip- sychotic treatment has been presented (Group G26).
• Preparation of different clinical guidelines: Tera- pia Psicológica Integral para Primeros Episodios Psicóticos (G10), PIENSA Guía para adolescen- tes y familiares que quieren entender y afrontar la psicosis (G01), Guía Clínica terapéutica para primeros episodios psicóticos en la infancia y la adolescencia (G01).
• Participation in the plan for mental health and in particular for creation of units for first psychotic episodes in the Comunidad Valenciana (G23).
• Reedition of the research meeting on Psychosis including the participation of patients’ relatives.
CIBERSAM I Annual report 2015 I 19